In this study, we identified KIAA1429 is a key molecule for predicting the efficacy of neoadjuvant therapy and prognosis in CRC, and found that BRAF can regulate its phosphorylation modification and change its localization, thereby further upregulating the WNT pathway to promote oxaliplatin resistance. Here, BRAF is linked to colorectal carcinoma.